Moderna Inc. (MRNA)
Moderna Statistics
Share Statistics
Moderna has 385.82M shares outstanding. The number of shares has increased by 0.67% in one year.
Shares Outstanding | 385.82M |
Shares Change (YoY) | 0.67% |
Shares Change (QoQ) | 0.26% |
Owned by Institutions (%) | 71.99% |
Shares Floating | 341.66M |
Failed to Deliver (FTD) Shares | 43.22K |
FTD / Avg. Volume | 0.36% |
Short Selling Information
The latest short interest is 43.01M, so 11.18% of the outstanding shares have been sold short.
Short Interest | 43.01M |
Short % of Shares Out | 11.18% |
Short % of Float | 12.53% |
Short Ratio (days to cover) | 4.04 |
Valuation Ratios
The PE ratio is -4.48 and the forward PE ratio is -5.07. Moderna's PEG ratio is 0.18.
PE Ratio | -4.48 |
Forward PE | -5.07 |
PS Ratio | 4.93 |
Forward PS | 1.2 |
PB Ratio | 1.46 |
P/FCF Ratio | -3.94 |
PEG Ratio | 0.18 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Moderna.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.67, with a Debt / Equity ratio of 0.07.
Current Ratio | 3.67 |
Quick Ratio | 3.62 |
Debt / Equity | 0.07 |
Debt / EBITDA | -0.21 |
Debt / FCF | -0.18 |
Interest Coverage | -164.38 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $557.93K |
Profits Per Employee | $-613.97K |
Employee Count | 5,800 |
Asset Turnover | 0.23 |
Inventory Turnover | 12.51 |
Taxes
Income Tax | -46M |
Effective Tax Rate | 1.28% |
Stock Price Statistics
The stock price has increased by -75.57% in the last 52 weeks. The beta is 2.23, so Moderna's price volatility has been higher than the market average.
Beta | 2.23 |
52-Week Price Change | -75.57% |
50-Day Moving Average | 33.72 |
200-Day Moving Average | 61.04 |
Relative Strength Index (RSI) | 29.13 |
Average Volume (20 Days) | 11.87M |
Income Statement
In the last 12 months, Moderna had revenue of 3.24B and earned -3.56B in profits. Earnings per share was -9.27.
Revenue | 3.24B |
Gross Profit | 1.77B |
Operating Income | -3.94B |
Net Income | -3.56B |
EBITDA | -3.39B |
EBIT | -3.58B |
Earnings Per Share (EPS) | -9.27 |
Balance Sheet
The company has 1.93B in cash and 710M in debt, giving a net cash position of 1.22B.
Cash & Cash Equivalents | 1.93B |
Total Debt | 710M |
Net Cash | 1.22B |
Retained Earnings | 10.04B |
Total Assets | 14.14B |
Working Capital | 5.89B |
Cash Flow
In the last 12 months, operating cash flow was -3B and capital expenditures -1.05B, giving a free cash flow of -4.05B.
Operating Cash Flow | -3B |
Capital Expenditures | -1.05B |
Free Cash Flow | -4.05B |
FCF Per Share | -10.56 |
Margins
Gross margin is 54.76%, with operating and profit margins of -121.91% and -110.04%.
Gross Margin | 54.76% |
Operating Margin | -121.91% |
Pretax Margin | -111.46% |
Profit Margin | -110.04% |
EBITDA Margin | -104.88% |
EBIT Margin | -121.91% |
FCF Margin | -125.31% |
Dividends & Yields
MRNA does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for MRNA is $50.5, which is 101% higher than the current price. The consensus rating is "Hold".
Price Target | $50.5 |
Price Target Difference | 101% |
Analyst Consensus | Hold |
Analyst Count | 20 |
Scores
Altman Z-Score | 2.72 |
Piotroski F-Score | 2 |